Table 4 The efficacy analysis based on the response status to platinum-based chemotherapy
From: Pegylated liposomal doxorubicin in patients with epithelial ovarian cancer
| Intention-to-treat population (N = 115) | Per-protocol population (N = 92a) | |||||
|---|---|---|---|---|---|---|
| Platinum-refractory (N = 36) | Platinum-resistant (N = 31) | Partial platinum-sensitive (N = 48) | Platinum-refractory (N = 25) | platinum-resistant (N = 26) | Partially platinum-sensitive (N = 41) | |
| Complete remission, No. (%) | 0, (0.0%) | 0, (0.0%) | 2, (4.2%) | 0, (0.0%) | 0, (0.0%) | 2, (4.9%) |
| Partial remission, No. (%) | 6, (16.7%) | 14, (45.2%) | 21, (43.8%) | 6, (24.0%) | 14, (53.8%) | 21, (51.2%) |
| Stable disease, No. (%) | 14, (38.9%) | 6, (19.4%) | 12, (25.0%) | 14, (56.0%) | 6, (23.1%) | 12, (29.3%) |
| Disease progression, No. (%) | 5, (13.9%) | 6, (19.4%) | 6, (12.5%) | 5, (20.0%) | 6, (23.1%) | 6, (14.6%) |
| ORRb, (95%CI) | 16.7% (3.9–29.5%) | 45.2% (26.6–63.7%) | 47.9% (33.3–62.6%) | 24.0% (6.0–42.0%) | 53.8% (33.3–74.4%) | 56.1% (40.2–72.0%) |
| DCRc, (95%CI) | 55.6% (38.5–72.6%) | 64.5% (46.7–82.4%) | 72.9% (59.9–86.0%) | 80.0% (63.1–96.9%) | 76.9% (59.6–94.3%) | 85.4%(74.1–96.7%) |